Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

6.070 -0.290 (-4.56%)
Streaming Delayed Price Updated: 3:02 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
RedChip's Biotech Virtual Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Via ACCESS Newswire
News headline image
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
From DiaMedica Therapeutics Inc
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.